Glenmark Pharmaceuticals Ltd
Pharmaceuticals & Biotechnology | Mid Cap
Health Score : 6.36Glenmark Pharmaceuticals demonstrates a mixed financial performance. The company shows very strong solvency and profitability, driven by effective debt management and robust returns on its capital, equity, and assets. Growth prospects are promising, particularly in revenue and operating profit, but are offset by declines in EPS and net income. Liquidity is acceptable, but there is room for improvement. Efficiency in asset utilization is a notable area of concern. Overall, while Glenmark exhibits financial strengths, addressing efficiency and select growth metrics will be crucial for sustained success. The company maintains a strong coverage ratio, indicating it can comfortably handle its interest and dividend obligations.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio6.00
- Financial Ratio5.20
- Profitability Ratio10.00
- Efficiency Ratio2.67
- Coverage Ratio10.00
- Solvency Ratio10.00
- Liquidity Ratio5.88
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourBullish
- 2 HoursBullish
- 4 HoursBullish
- 1 DayNeutral
- 1 WeekNeutral
- 1 MonthNeutral
Health Score : 6.36Glenmark Pharmaceuticals demonstrates a mixed financial performance. The company shows very strong solvency and profitability, driven by effective debt management and robust returns on its capital, equity, and assets. Growth prospects are promising, particularly in revenue and operating profit, but are offset by declines in EPS and net income. Liquidity is acceptable, but there is room for improvement. Efficiency in asset utilization is a notable area of concern. Overall, while Glenmark exhibits financial strengths, addressing efficiency and select growth metrics will be crucial for sustained success. The company maintains a strong coverage ratio, indicating it can comfortably handle its interest and dividend obligations.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
Overall Valuation Score
P/E RATIO (TTM)
-310.90
Industry Median
28.62
Mid Cap Median
36.34
P/E RATIO
45.87
P/B RATIO
5.95
Industry Median
3.17
Mid Cap Median
7.64
P/S RATIO
3.68
Industry Median
3.42
Mid Cap Median
6.30
Others
PEG RATIO
0.00
EV/EBITDA RATIO
22.37
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹2213.6 as on Jun 21, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
Quarterly Report⬤30th Jan 26
Quarterly Financial Results Q3 FY 2025-26
NEUTRAL SENTIMENT
Growth Score : 6.00The company demonstrates mixed growth performance. While revenue and operating profit growth are strong, indicating market expansion and improved operational efficiency, EPS and net income growth are negative. This suggests that profitability is not keeping pace with revenue growth, potentially due to rising costs or other factors impacting the bottom line. The weighted average calculation emphasizes recent performance, reflecting the company's present growth trends.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthPoorAsset Growth RateExcellentNet Income Growth RatePoor| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 12.44 | -5.87 | 1.99 | 12.77 | 27.48 |
| Operating Profit Growth Rate | 11.66 | -29.74 | -26.91 | 96.74 | 94.47 |
| Earnings Per Share (EPS) Growth | -2.94 | -68.44 | -605.41 | -169.73 | 30.05 |
| Asset Growth Rate | 9.48 | 13.6 | -25.88 | 11.37 | 24.5 |
| Net Income Growth Rate | 2.47 | -62.07 | -480.37 | -173.01 | 30.09 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Financial Score : 5.20The company's financial metrics present a mixed view. While cash earnings per share and book value per share are strong, indicating solid underlying financial health, adjusted earnings per share and capital expenditures are areas of concern. Dividend per share reflects a moderate return to shareholders. The weighted average calculation emphasizes recent performance, reflecting the company's present financial position.
Adjusted Earnings Per Share (Adjusted EPS)PoorCash Earnings Per Share (Cash EPS)ExcellentBook Value Per ShareExcellentDividend Per Share (DPS)AverageCapital Expenditures (CapEx)Poor| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 43.29 | 27.46 | -154.93 | 47.07 | 105.43 |
| Cash Earnings Per Share (Cash EPS) | 52.89 | 33.79 | -30.43 | 54.75 | 69.11 |
| Book Value Per Share | 324.5 | 338.36 | 280.29 | 316.04 | 375.43 |
| Dividend Per Share (DPS) | 2.34 | 2.53 | 2.66 | 2.6 | 2.41 |
| Capital Expenditures (CapEx) | 788 | 551 | 896 | 748 | 1356 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
Profitability Score : 10.00The company exhibits strong profitability, characterized by high gross profit margin, ROCE, ROE, ROA, operating margin, and net margin. This reflects efficient operations and effective cost management. The weighted average calculation emphasizes recent performance, reflecting the company's present profitability.
Gross Profit MarginExcellentReturn on Capital Employed (ROCE)ExcellentReturn on Equity (ROE)ExcellentReturn on Assets (ROA)ExcellentOperating MarginExcellentNet MarginExcellent| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 14.95 | 9.2 | 5.19 | 14 | 23.55 |
| Return on Capital Employed (ROCE) | 16 | 10 | 12 | 19 | 40 |
| Return on Equity (ROE) | 10.94 | 3.98 | -18.27 | 11.83 | 12.96 |
| Return on Assets (ROA) | 13.65 | 8.44 | 8.32 | 14.7 | 22.97 |
| Operating Margin | 18.91 | 14.12 | 10.12 | 17.65 | 26.92 |
| Net Margin | 8.08 | 3.25 | -12.14 | 7.86 | 8.02 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
Efficiency Score : 2.67The company's efficiency in utilizing its assets is a notable area of concern. Low turnover ratios across fixed assets, inventory, receivables, and capital suggest inefficiencies in asset management. Extended days sales in inventory and receivable days indicate challenges in converting inventory and receivables into cash. The weighted average calculation emphasizes recent performance, reflecting the company's present asset management.
Fixed Asset Turnover RatioPoorInventory Turnover RatioWeakReceivables Turnover RatioWeakDays Sales in Inventory RatioPoorReceivable DaysPoorCapital Turnover RatioPoor| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 2.09 | 2.14 | 2.81 | 2.97 | 2.66 |
| Inventory Turnover Ratio | 4.38 | 4.32 | 4.58 | 4.13 | 4.02 |
| Receivables Turnover Ratio | 4.34 | 3.42 | 4.28 | 5.12 | 4.09 |
| Days Sales in Inventory Ratio | 83.33 | 84.49 | 79.69 | 88.38 | 90.8 |
| Receivable Days | 84.1 | 106.73 | 85.28 | 71.29 | 89.24 |
| Capital Turnover Ratio | 1.03 | 0.85 | 1.46 | 1.38 | 1.53 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
Coverage Score : 10.00The company exhibits a strong coverage position, indicating a high ability to meet its interest and dividend obligations. This reflects a solid financial foundation and reduces the risk of financial distress. The weighted average calculation emphasizes recent performance, reflecting the company's present coverage capacity.
Interest Coverage RatioExcellentEquity Dividend Coverage RatioExcellent| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 5.84 | 3.03 | 1.84 | 7.76 | 10.5 |
| Equity Dividend Coverage Ratio | 14.29 | 4.17 | 14.29 | 20 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
Solvency Score : 10.00The company exhibits a strong solvency position, characterized by low debt levels relative to equity and assets. This indicates a conservative capital structure with a significant reliance on equity financing. Such a structure reduces financial risk and provides a solid foundation for long-term stability. The low debt ratios reflect effective debt management and a strong equity base.
Debt RatioExcellentDebt to Equity RatioExcellentEquity RatioExcellentDebt To Asset RatioExcellent| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0.24 | 0.3 | 0.03 | 0.08 | 0.05 |
| Debt to Equity Ratio | 0.32 | 0.43 | 0.03 | 0.09 | 0.05 |
| Equity Ratio | 0.76 | 0.7 | 0.97 | 0.92 | 0.95 |
| Debt To Asset Ratio | 0.17 | 0.21 | 0.02 | 0.05 | 0.03 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
Liquidity Score : 5.88The liquidity position reflects an ability to meet its short-term obligations, partially supported by liquid assets. The current and quick ratios suggest there are adequate resources to cover immediate liabilities. However, reliance on operational cash flow is a potential concern. The operating cash flow ratio is low, indicating potential challenges in using operations to cover short-term liabilities.
Current RatioAverageQuick RatioGoodCash RatioAverageOperating Cash Flow RatioPoor| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 1.98 | 2.2 | 1.39 | 1.67 | 1.48 |
| Quick Ratio | 1.49 | 1.79 | 0.99 | 1.19 | 1.09 |
| Cash Ratio | 0.28 | 0.2 | 0.26 | 0.27 | 0.13 |
| Operating Cash Flow Ratio | 0.22 | 0.11 | -0.04 | -0.13 | 0.39 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Abbott India Ltd | 8.68 | 35.89 | Neutral | 1892.00 | 730.39 | 1552.00 |
| 2 | Glaxosmithkline Pharmaceuticals Ltd | 8.38 | 38.14 | Neutral | 1309.00 | 59.73 | 1036.00 |
| 3 | J B Chemicals & Pharmaceuticals Ltd | 8.14 | 49.64 | Overvalued | 1107.00 | 41.98 | 709.00 |
| 4 | Alkem Laboratories Ltd | 8.08 | 27.91 | Neutral | 3005.00 | 182.76 | 2351.00 |
| 5 | Gland Pharma Ltd | 7.91 | 35.27 | Overvalued | 1630.00 | 78.88 | 1027.00 |
| 6 | Neuland Laboratories Ltd | 7.84 | 61.14 | Highly Overvalued | 574.00 | 283.01 | 364.00 |
| 7 | Ajanta Pharma Ltd | 7.72 | 36.27 | Neutral | 1395.00 | 75.78 | 1056.00 |
| 8 | Syngene International Ltd | 7.44 | 56.08 | Overvalued | 918.00 | 7.55 | 317.00 |
| 9 | Emcure Pharmaceuticals Ltd | 7.40 | 36.42 | Neutral | 1865.00 | 38.66 | 941.00 |
| 10 | Laurus Labs Ltd | 7.10 | 85.84 | Neutral | 1778.00 | 13.72 | 890.00 |
| 11 | Glenmark Pharmaceuticals Ltd | 6.36 | 45.87 | Neutral | 4572.00 | -7.12 | 1362.00 |
| 12 | Ipca Laboratories Ltd | 6.33 | 35.26 | Neutral | 1979.00 | 44.64 | 1184.00 |
| 13 | Piramal Pharma Ltd | 5.83 | -64.86 | Neutral | 922.00 | 5.27 | -326.00 |
| 14 | Pfizer Ltd | 3.45 | 45.16 | Neutral | -82.00 | 157.92 | 300.00 |
Balanced ManagementThe management of Glenmark Pharmaceuticals exhibits a mixed performance. The company has shown strong compounded profit growth in the long term and has maintained a consistent promoter holding, reflecting stability. However, there are concerns regarding the volatility in sales and profit growth, particularly the negative profit growth in recent years. The fluctuating operating profit margin and reliance on other income raise questions about the sustainability of core operations.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Promoter Holding | 46.65% | Consistent promoter holding indicates confidence. |
| Compounded Profit Growth (10 Years) | 17% | Strong long-term profit growth. | |
| CONS | Volatility in Sales Growth | Fluctuating | Sales growth has been inconsistent. |
| Negative Profit Growth (Recent Years) | -1,434 Cr. (Mar 2024) | Significant negative profit growth in recent periods. |
Financial Performance & GrowthAverageCapital Efficiency & ReturnsGoodFinancial Health & PrudenceAverageShareholding & Ownership StructureGoodFinancial Performance & Growth
Glenmark Pharmaceuticals demonstrates mixed financial growth. Compounded sales growth shows a moderate trend, while profit growth exhibits significant volatility. Recent negative profit growth and fluctuating OPM % raise concerns.
| Metric | 2014–2016 | 2017–2019 | 2020–2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | 13.4% | 9.5% | 8.6% | 3% | 2% | 13% |
| Compounded Profit Growth | 18.5% | -2.4% | -0.8% | 6% | 130% | 130% |
While sales have shown some growth, the inconsistency in profit and OPM suggests operational challenges. Variability in other income further impacts net profitability, indicating reliance beyond core operations.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| YOY Sales Growth % | 12.44% | -6.33% | -4.11% | -2.31% | -5.86% | 6.85% | 7.06% | 35.14% | 6.31% |
| YOY Profit Growth % | -15% | -37% | 1% | -49% | -34% | 91% | 297% | 193% | 116% |
Capital Efficiency & Returns
Glenmark Pharmaceuticals shows good capital efficiency as indicated by ROCE and ROE. Returns on capital and equity are very good, suggesting effective use of funds. However, trends in asset turnover and cash conversion cycle need consideration.
| Metric | Mar 2014 | Mar 2017 | Mar 2020 | Mar 2023 | Mar 2025 |
|---|---|---|---|---|---|
| ROCE % | 15% | 21% | 14% | 10% | 19% |
A declining ROCE trend over the years, with a recent uptick, suggests fluctuating efficiency. Effective working capital management is crucial for maintaining these returns.
Financial Health & Prudence
Glenmark Pharmaceuticals exhibits moderate financial health. While the company has managed debt, the interest coverage ratio and dividend payout need careful consideration. The debt-to-equity ratio and the enterprise value relative to market cap plus debt provide insights into leverage and financial obligations.
| Metric | Mar 2014 | Mar 2017 | Mar 2020 | Mar 2023 | Mar 2025 |
|---|---|---|---|---|---|
| Borrowings | 3,267 | 4,724 | 4,869 | 4,608 | 2,473 |
Borrowings have fluctuated over the years, indicating active debt management.
Shareholding & Ownership Structure
Glenmark Pharmaceuticals demonstrates a consistent promoter holding, indicating confidence and alignment with shareholders. Institutional holding (FII/DII) reflects attractiveness to investors, providing stability.
| Metric | Jun 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Promoters + | 46.65% | 46.65% | 46.65% | 46.65% |
| FIIs + | 24.23% | 22.47% | 21.38% | 23.15% |
| DIIs + | 10.50% | 10.40% | 13.36% | 14.60% |
Stable promoter holding aligns management interests with shareholder value. Active institutional participation enhances market confidence and liquidity.
Balanced RiskThe risk assessment for Glenmark Pharmaceuticals reveals a moderate level of concern. The segment performance volatility and foreign exchange exposure contribute to the overall risk profile. Recent negative cash flows from operating activities raise concerns about short-term liquidity. Careful monitoring and proactive risk management strategies are necessary to mitigate potential adverse impacts on financial stability and performance.
Segment performance volatilityAverageForeign exchange or interest rate exposureAverageRegulatory compliance cost trendsAverageSegment performance volatility
Fluctuations in quarterly sales and operating profit margins indicate inconsistent segment performance.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 |
|---|---|---|---|---|---|
| OPM % | 15.35% | 15.54% | 15.87% | 15.29% | 13.26% |
The varying performance highlights the need for proactive management of diverse segments to ensure consistent financial health.
Foreign exchange or interest rate exposure
Fluctuations in other income along with borrowings indicates exposure to foreign exchange and interest rate risks.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Other Income - | -101 | -10 | 336 | -259 |
| Borrowings | 3,962 | 4,608 | 1,231 | 2,473 |
Monitoring exchange rates and interest obligations is crucial for mitigating financial uncertainties.
Regulatory compliance cost trends
Employee cost % exhibits trend which indicates rising regulatory compliance cost trends and close monitoring is needed.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|
| Employee Cost % | 19.90% | 22.46% | 24.29% | 22.69% |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 102180.48Bullish
- SMA 202159.17Bullish
- SMA 502155.85Bullish
- EMA 102184.39Bullish
- EMA 202170.75Bullish
- EMA 502166.74Bullish
- DEMA 102203.67Bullish
- DEMA 202185.77Bullish
- DEMA 502154.96Bullish
- TEMA 102211.81Bearish
- TEMA 202200.49Bullish
- TEMA 502172.81Bullish
- MACD13.24Bullish
- ADX27.01Strong Trend
- IndicatorValueSignal
- RSI69.13Neutral
- CCI141.17Overbought
- ROC 92.55Bullish
- ROC 143.11Bullish
- ROC 252.42Bullish
- Stoch K88.89Overbought
- Stoch D90.55Overbought
- IndicatorValueSignal
- BB Upper2211.35Neutral
- BB Middle2159.17Neutral
- BB Lower2106.99Neutral
- ATR16.97High Volatility
- IndicatorValueSignal
- MFI76.82Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 102165.58Bullish
- SMA 202157.54Bullish
- SMA 502167.64Bullish
- EMA 102176.23Bullish
- EMA 202167.03Bullish
- EMA 502181.92Bullish
- DEMA 102193.90Bullish
- DEMA 202171.51Bullish
- DEMA 502141.93Bullish
- TEMA 102206.96Bearish
- TEMA 202188.26Bullish
- TEMA 502146.02Bullish
- MACD5.83Bullish
- ADX17.04Weak Trend
- IndicatorValueSignal
- RSI62.63Neutral
- CCI204.50Overbought
- ROC 93.26Bullish
- ROC 143.27Bullish
- ROC 252.82Bullish
- Stoch K91.62Overbought
- Stoch D90.13Overbought
- IndicatorValueSignal
- BB Upper2202.88Overbought
- BB Middle2157.54Neutral
- BB Lower2112.20Neutral
- ATR24.13High Volatility
- IndicatorValueSignal
- MFI69.86Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 102156.02Bullish
- SMA 202163.90Bullish
- SMA 502240.16Bearish
- EMA 102165.93Bullish
- EMA 202172.65Bullish
- EMA 502213.49Bearish
- DEMA 102170.55Bullish
- DEMA 202146.13Bullish
- DEMA 502170.52Bullish
- TEMA 102185.52Bullish
- TEMA 202159.87Bullish
- TEMA 50N/AN/A
- MACD-16.35Bullish
- ADX17.79Weak Trend
- IndicatorValueSignal
- RSI54.30Neutral
- CCI143.55Overbought
- ROC 92.70Bullish
- ROC 142.74Bullish
- ROC 252.50Bullish
- Stoch K72.00Neutral
- Stoch D50.84Neutral
- IndicatorValueSignal
- BB Upper2209.37Neutral
- BB Middle2163.90Neutral
- BB Lower2118.44Neutral
- ATR40.17Low Volatility
- IndicatorValueSignal
- MFI55.35Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 102166.63Bullish
- SMA 202209.01Bullish
- SMA 502270.35Bearish
- SMA 1002170.30Bullish
- SMA 2002064.05Bullish
- EMA 102177.35Bullish
- EMA 202205.17Bullish
- EMA 502223.95Bearish
- EMA 1002176.73Bullish
- EMA 2002066.38Bullish
- DEMA 102156.06Bullish
- DEMA 202159.15Bullish
- DEMA 502249.19Bearish
- DEMA 1002285.58Bearish
- DEMA 2002283.10Bearish
- TEMA 102170.66Bullish
- TEMA 202132.87Bullish
- TEMA 502202.01Bullish
- TEMA 1002278.91Bearish
- TEMA 2002289.59Bearish
- MACD-34.36Bearish
- ADX26.11Strong Trend
- IndicatorValueSignal
- RSI49.40Neutral
- CCI-21.64Neutral
- ROC 140.56Bullish
- ROC 25-5.43Bearish
- Stoch K37.61Neutral
- Stoch D22.80Neutral
- IndicatorValueSignal
- BB Upper2352.80Neutral
- BB Middle2209.01Neutral
- BB Lower2065.22Neutral
- ATR68.06High Volatility
- IndicatorValueSignal
- MFI38.51Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 202173.73Bullish
- SMA 502061.33Bullish
- EMA 202181.08Bearish
- EMA 502023.19Bullish
- DEMA 202283.48Bearish
- DEMA 502274.35Bearish
- TEMA 202281.14Bearish
- TEMA 502282.97Bearish
- MACD72.91Bearish
- ADX26.89Strong Trend
- IndicatorValueSignal
- RSI54.95Neutral
- CCI68.42Neutral
- ROC 142.33Bullish
- ROC 259.12Bullish
- Stoch K46.99Neutral
- Stoch D54.37Neutral
- IndicatorValueSignal
- BB Upper2428.28Neutral
- BB Middle2173.73Neutral
- BB Lower1919.18Neutral
- ATR143.50Low Volatility
- IndicatorValueSignal
- MFI40.52Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 62166.78Bullish
- SMA 122050.22Bullish
- SMA 241777.12Bullish
- EMA 62180.88Bullish
- EMA 122030.35Bullish
- EMA 241769.32Bullish
- DEMA 62315.24Bearish
- DEMA 122291.61Bearish
- DEMA 242219.31Bullish
- TEMA 62324.66Bearish
- TEMA 122312.17Bearish
- TEMA 242324.09Bearish
- MACD443.30Bullish
- ADX52.92Strong Trend
- IndicatorValueSignal
- RSI67.27Neutral
- CCI134.66Overbought
- ROC 25115.18Bullish
- ROC 50414.68Bullish
- Stoch K80.28Overbought
- Stoch D79.35Neutral
- IndicatorValueSignal
- BB Upper2453.20Neutral
- BB Middle1827.32Neutral
- BB Lower1201.44Neutral
- ATR242.25Low Volatility
- IndicatorValueSignal
- MFI79.73Neutral